Business Context and Reporting Period
Company: DexCom, Inc. (DXCM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management. Key products include the G6 and G7 integrated CGM systems and Stelo, an over-the-counter biosensor launched in August 2024 for adults with prediabetes and Type 2 diabetes not using insulin. The company operates globally with manufacturing facilities in the U.S., Malaysia, and a new facility under construction in Ireland.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue | $4,033.0 | $3,622.3 | +11% |
| Gross Profit | $2,438.2 | $2,288.9 | +7% |
| Gross Margin | 60.5% | 63.2% | -270 bps |
| Operating Income | $600.0 | $597.7 | +0.4% |
| Net Income | $576.2 | $541.5 | +6% |
| Diluted EPS | $1.42 | $1.30 | +9% |
| Operating Cash Flow | $989.5 | $748.5 | +32% |
| Cash & Equivalents (End of Period) | $2,580.0 | $2,720.0 | -5% |
Debt & Liquidity: As of December 31, 2024, the company held $2.58 billion in cash, cash equivalents, and short-term marketable securities. Total senior convertible notes outstanding were $2.46 billion ($1.21 billion due 2025 and $1.25 billion due 2028). The company had no outstanding borrowings under its $200 million revolving credit facility, with $192.3 million available.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by increased sales volume of disposable sensors, adding approximately 500,000 to 600,000 net users globally (excluding Stelo). International revenue grew 15% to $1.14 billion, while U.S. revenue grew 10% to $2.89 billion.
- Margin Compression: Gross margin decreased from 63.2% to 60.5%. This was attributed to product and channel mix changes, higher freight costs, and specific non-cash charges including a $22.7 million inventory build charge and $20.6 million in inventory damaged in transit or due to yield issues.
- Expense Increases: Operating expenses rose 9% to $1.84 billion. Selling, general, and administrative (SG&A) expenses increased by $100.4 million, driven by higher advertising ($33.5 million), compensation ($30.7 million), and software/data costs ($18.0 million). R&D expenses increased by $46.6 million due to higher headcount, clinical trials, and software costs.
- Legal Resolution: In December 2024, DexCom entered into a settlement and patent cross-license agreement with Abbott Diabetes Care to resolve all pending patent litigation. The agreement involves no royalty payments or financial compensation.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects continued growth driven by the expansion of the customer base and the commercialization of Stelo. The company is investing heavily in manufacturing capacity, including a new facility in Ireland, to address supply constraints. The company anticipates seasonality with lower sales in Q1 due to insurance deductible resets.
Key Risks & Contingencies:
- Manufacturing Constraints: The company recently experienced manufacturing and inventory challenges for the G7 system, leading to supply disruptions in certain markets. Scaling capacity remains a critical risk.
- Reimbursement & Pricing: Ongoing pressure from third-party payors and managed care organizations to reduce costs could lead to lower reimbursement rates or pricing headwinds.
- Legal Proceedings: Pending securities class action litigation and derivative actions allege false statements regarding 2024 revenue expectations. The company intends to defend these vigorously.
- Supply Chain: Reliance on single-source suppliers for critical components (e.g., ASICs, polymers) creates vulnerability to supply disruptions.
Investor Verification Checklist
- Manufacturing Capacity: Verify the timeline for resolving G7 supply constraints and the operational readiness of the new Ireland facility.
- Stelo Adoption: Monitor early adoption rates and reimbursement status for the new over-the-counter Stelo product.
- Reimbursement Trends: Track changes in coverage policies from major payors and the impact of Medicare/Medicaid policy shifts on net pricing.
- Legal Exposure: Review developments in the pending securities class action litigation regarding 2024 revenue guidance.
- Debt Maturity: Assess the company's liquidity position relative to the $1.21 billion convertible note maturity in November 2025.